Clinical Trial Detail

NCT ID NCT02225405
Title Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Docetaxel + Nintedanib

Age Groups: adult

No variant requirements are available.